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Prevalence of Hepatitis C Virus in Lymphoproliferative Disorders
F. Bilwani, Y. Zaidi, G. N. Kakepoto, S. N. Adil, M. Khurshid
Department of Pathology, The Aga Khan University Hospital, Karachi.

Abstract
Objective: To study the prevalence of hepatitis C virus in lymphoproliferative disorders.
Methods: A case control prospective study was performed on 143 patients with lymphoproliferative disorders
and 29 patients with non-hematological malignancies were taken as controls. All the patients in both groups were
analyzed for various risk factors for infection with hepatitis C virus and were tested for the presence of hepatitis
C virus antibody (anti HCV), cryoglobulins and rheumatoid factor antibody. Hepatitis C viremia was documented
by detection of HCV RNA by polymerase chain reaction.
Results: There was no significant difference for risk factors for hepatitis C virus infection in both the groups
except for the increase in number of surgical procedures being carried out in the control group. There was no
significant difference in the presence of rheumatoid factor antibody in both the groups and cryoglobulins were
not positive in any individual. Five percent patients with lymphoproliferative disorders and 3.4% with nonhematological malignancies were positive for anti HCV. HCV RNA was detected in 29.2% cases and 31.0% in
controls.
Conclusion: There was no association between hepatitis C virus infection and lymphoproliferative disorder in
our population. However, further studies are required from this region to establish any causal relationship
between hepatitis C virus infection and lymphoproliferative disorder (JPMA 54:202;2004).

Introduction
Hepatitis C virus has recently been implicated in the
etiology of lymphoproliferative disorders. Hepatitis C virus
(HCV) is an RNA virus that belongs to the family of
flavivirus. The natural targets of HCV are hepatocytes and
possibly B-lymphocytes.1 In infected patients, HCV-related
antigens have been found in peripheral blood B and T
lymphocytes, lymph nodes and lymphocytes infiltrating the
liver.2 Eli Zukerman et al have reported a higher prevalence
of monoclonal Ig H rearrangement and bcl - 2 translocation
in patients with hepatitis infection than in patients with
chronic liver disease of other etiologies. These data also
suggest that HCV may play a role in the multistep
mechanism of lymphomagenesis by inducing proliferation
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of B cell and inhibition of apoptosis.3
It has also been postulated that the association between
HCV infection, mixed cryoglobulinemia and lymphoplasmacytic
lymphoma raises the possibility that HCV may be initiating
agent or a cofactor in the pathogenesis of non-Hodgkin's
Lymphoma.2 Previous studies clearly show a relationship
between HCV and mixed cryoglobulinemia, a condition that is
strongly associated with lymphoplasmacytic lymphoma, a low
grade B cell NHL.4 Study conducted by Linda et al found that
HCV 2 a and 3 genotype was detected with higher prevalence
in patients with mixed cryoglobulinemia than in controls.5 It
has also been found that haplotype HLA - B8 and DR 3 is
strongly associated with the development of HCV - related
mixed cryoglobulinemia.
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There is no published data regarding association
between Hepatitis C virus and the lymphoproliferative
disorders from Pakistan. The aim of this study was to find
out the prevalence of hepatitis C in patients with
lymphoprolierative disorders in our population.

Patients, Methods and Results
This prospective case control study was carried out
from June 1998 to June 2001 at Aga Khan University and
Hospital on diagnosed patients of lymphoproliferative
disorders and non -hematological malignancies.
Patients with various lymphoproliferative disorders
attending hematology oncology wards and outpatient clinics
at Aga Khan University and Hospital were included in the
study as cases. Patients with non-hematological
malignancies were chosen as controls.
The only exclusion criterion was patients who did
not consent to give information and blood sample for the
study. All patients with lymphoproliferative disorders were
diagnosed according to the criteria set by REAL (Revised
European American Lymphoma) classification6, using
histological and immunologic techniques along with their
clinical presentations. Two pathologists performed the
microscopic examination of the material provided for the
diagnosis.
Table 1. Distribution of patients with lymphoproliferative disorders
(n=143).
Types of lymphoproliferative disorder

Frequency

%

Hodgkin's disease (Nodular sclerosis)

7

4.9

Hodgkin's disease (Mixed cellularity)

8

5.6

27

18.9

Follicular / Low grade NHL

8

5.6

Small lymphocytic lymphoma

3

2.1

T cell non - Hodgkin's lymphoma

6

4.2

Marginal zone lymphoma

1

0.7

MALToma

1

0.7

24

16.8

2

1.4

28

19.6

2

1.4

26

18.2

Diffuse non - Hodgkin's lymphoma

Multiple myeloma
Waldernstroms macroglobulinemia
Chronic lymphocytic leukemia
Hairy cell leukemia
Acute lymphoblastic leukemia

All of the non-hematological malignancies were
diagnosed on histological examination of the excised tumor
mass. Diagnosis of hepatitis C virus infection was made if
patients were tested positive for the hepatitis C antibody by
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ELISA and for hepatitis C RNA by PCR (polymerase chain
reaction). Sample size was calculated by using Epi Info
program.
Questions asked for the assessment of risk of
acquiring hepatitis C infection included history of blood
transfusion, intravenous drug abuse, needle stick injury,
history of surgical procedures, hepatitis C in sexual partner
and also history of therapeutic injections. Patients were also
inquired about the history of presence of autoimmune
features such as dry eyes, dry mouth, purpura, arthralgias
and numbness of limbs. Blood samples were tested for
serum cryoglobulins, rheumatoid factor antibody, hepatitis
C virus antibody and hepatitis C virus RNA by polymerase
chain reaction.
Table 2. Distribution of patients with non-haematological
malignancies (n=29).
Type of malignancy

Frequency

%

Ca Breast

9

31.6

Transitional cell Ca of Bladder

3

10.3

Ca Colon

3

10.3

Ca Caecum

1

3.4

Ca nasopharynx

1

3.4

Squamous cell Ca of Palate

1

3.4

Osteogenic Sarcoma

1

3.4

Adeno Ca of Stomach

1

3.4

Choroid Carcinoma

1

3.4

Ca Ovary

1

3.4

Ca Parotid

1

3.4

Ewing's Sarcoma

1

3.4

Ca Lung

1

3.4

Ca Esophagus

1

3.4

Ca Prostate

1

3.4

Abdominal Sarcoma

1

3.4

Embryonal Rhabdomyosarcoma

1

3.4

Cryoglobulins were performed by manual method.7
Rheumatoid factor reagent8 was performed by agglutination
slide test (RF LATEX TEST, RANDOX laboratories Ltd.
UK).There is an association between high rheumatoid factor
(RF) activity and hepatitis C virus viral replication and
selection of monoclonal or oligoclonal rheumatoid factor
secreting B cells. 9 It has also been mentioned that
rheumatoid factor are also induced during normal antiviral or
antibacterial immune responses. In keeping with evidence
given above we also looked for the presence of
cryoglobulins and rheumatoid factor (RF) activity along with
anti HCV antibodies and HCV RNA by PCR in our patients.
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Table 3. Analysis of variables related to the risk of hepatitis C
infection.
Cases

Control

(n=143)

(n=29)

P value

Table 4. Results of RF antibody, cryoglobulins and hepatitis C
antibody.
Test

Cases

Controls Odds ratio

(n=143)

History of blood transfusion

(n=29)

P

(95% CI)

value

NA

NA

NA

NA

Rheumatoid factor

Yes

49 (34.3%)

10 (34.5%)

No

94 (65.7%)

19 (65.5%)

1.000

Antibody
Positive

12 (8.4%)

Negative

131 (91.6%)

29 (100%)

0

Positive

0

0

Negative

143 (100%)

29 (100%)

Positive

7 (4.9%)

1 (3.4%)

1.441

Negative

136 (95.1%)

28 (96.6%)

(0.171,

History of surgery
Yes

24 (16.8%)

26 (89.7%)

No

119 (83.2%)

3 (10.3%)

0.000

Cryoglobulins

History of IV drug abuse
Yes

0

0

No

143 (100%)

29 (100%)

NA

Hepatitis C antibody

History of needle stick

1.000

12.18)

injury
Yes

0

No

143 (100%)

0

NA
Table 5. Results of hepatitis C virus detection by polymerase chain
reaction.

29 (100%)

History of hepatitis C

Cases
(n=48)

in sexual partner
Yes
No

0
143 (100%)

0

Odds radio
(95% CI)

P
value

0.915

1.00

NA

29 (100%)

History of therapeutic
injections

Positive

14 (29.2%)

9 (31.0%)

Negative

34 (70.8%)

20 (69.0%)

0.336,
2.049)

Yes

1 (0.7%)

1 (3.4%)

No

142 (99.3%)

28 (96.6%)

0.310

One hundred and forty three patients with
lymphoproliferative disorders were enrolled as cases and 29
patients with non-hematological malignancies taken as
controls.

History of features of
autoimmune disease
Yes

7 (4.9%)

1 (3.4%)

No

136 (95.1%)

28 (96.6%)

1.000

Anti-HCV antibodies were performed using 3rd
generation ELISA method (AXSYM HCV version 3.0,
Abbott, Illinois, U.S.A.). Patients were also screened for
hepatitis C viremia by PCR performed by reverse
transcriptase polymerase chain reaction (AMPLICOR,
ROCHE, Indianapolis, U.S.A.).
Statistical analysis was performed using risk
estimate, calculated, by using odds ratio, Chi-square test
and logistic regression for multivariate analysis.
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Controls
(n=29)

Distribution of patients with lymphoproliferative
disorders are given in Table 1. There were 94 males (65.7%)
and 49 (34.3%) females and 12 (41.4%) males and 17 (58.6
%).in the mean age non-lymphoproliferative group.
Lymphoproliferative disorder was 43 years (range 5-85
years) and in non-lymphoproliferative group was 50 years
(range 12-73). Difference was insignificant.
All the patients in both the groups were analyzed for
various variables related to the risk factors for hepatitis C
virus infection. History of surgery was the only risk factor
for hepatitis C infection that was significantly different in
both the groups. All the patients were also analyzed for
rheumatoid factor antibody, cryoglobulins and hepatitis C
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antibody. Other results also revealed that there is no
significant difference in presence of rheumatoid factor
antibody in both the groups and the risk of high titers of RF
antibody was not increased in patients with
lymphoproliferative disorder. Cryoglobulins were not
positive in any individual.
Hepatitis C virus RNA was then detected by
polymerase chain reaction (PCR). All the controls were
analyzed for hepatitis C using this method while 48 patients
with lymphoproliferative disorders were analyzed for
hepatitis C by PCR. Results for hepatitis C by PCR are
given in Table 3.
The results of analysis of patients for hepatitis C
infection by polymerase chain reaction and by detection of
hepatitis C antibody in both cases and control group showed
that there is no statistically significant difference between
both the groups for the presence of hepatitis C infection.
Also the risk estimate calculated by odds ratio showed that
there is no association between hepatitis C virus infection
and lymphoproliferative disorder.
Since no disease association with hepatitis C
infection was established and not more than one of the risk
factors for hepatitis C infection was found to be significant,
hence multivariate analysis was not done.

Comments
Our study suggest a low prevalence of hepatitis C
virus infection in lymphoproliferative disorder in contrast to
relatively high rates seen in Italian10 , Romanian11 and
Japanese population. 12
In our study we have analyzed a broad and
heterogeneous group of lymphoproliferative disorder along
with a diverse group of non - hematological malignancies.
Rate of hepatitis C virus infection in Pakistan is 1 to
6 % as found in large population of healthy blood donors
tested for hepatitis C virus antibody.13-15 The rate of
positivity for hepatitis C infection in our group of
lymphoproliferative disorder was not found to be higher as
compared to the rate estimated to be in our general
population. Comparing the rate of hepatitis C virus antibody
positivity and hepatitis C viremia in our patients with
lymphoproliferative disorders and the control group, it was
found that there is no significant difference between the two
groups.
Our findings are more in agreement with that of Mc
coll et al who have suggested no association between
lymphoproliferative disorder and hepatitis C virus
infection.16
Our results are however in contrast to that reported
in Italy by Ferri et al.17 The high prevalence of this infection
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in a corresponding Italian population does suggest a
possible role. But the argument in relation to this finding
was that since prevalence of hepatitis C virus infection was
higher in this population, this hypothesis given by Ferri et al
requires further explanation.
Studies done previously have mentioned that
hepatitis C virus infection is associated with mixed
cryoglobulinemia.18 However in our study cryoglobulins
were not detected in patients found to be positive for
hepatitis C antibody or for hepatitis C viremia by
polymerase chain reaction.
Recent literature also suggested that there is an
association between hepatitis C viral replication and
rheumatoid factor activity. In our study 12 (8.4%) patients
with lymphoproliferative disorders were positive for
rheumatoid factor antibody. None of these patients tested
positive for hepatitis C viremia.
As far as various risk factors for hepatitis C are
concerned, there was no significant difference between the
two groups .The only significantly different risk factor was
the higher number of surgical procedures being carried out
in the control group. This could be explained by the fact that
most of the patients in this category underwent surgery at
the time of diagnosis of their malignancies.
We suggest that most probably geographical
difference may be decisive in the etiopathogenesis of such
heterogeneous and multifactorial malignancies. In
particular, different infectious agent, genetic or
environmental factors may variably be combined in patient
population from different countries.
Further studies are required from our region and also
from other parts of the world to establish the causal
relationship between hepatitis C virus infection and
lymphoproliferative disorder.
In view of our data we conclude that there seems to
be no association between hepatitis C virus infection and
lymphoproliferative disorder in our population. No major
differences were observed for hepatitis C viremia in patients
with lymphoproliferative disorder and with nonhematological malignancies.
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Review Article
Chemical and Biological Warfare preparing to meet the Threat
S. Sophie, S.U. Haq, M. R. Khan*
Departments of Anesthesiology and Surgery*, The Aga Khan University Hospital, Karachi.

Introduction
Till the recent past, there was a widespread tendency
to think about defence against chemical and biological
warfare (CBW) agents as unnecessary, as someone else's
responsibility, or as simply too difficult. 1 The threat of
exposure to such agents has traditionally been considered a
military issue. Several recent events, however, have
demonstrated that civilians may also be exposed to these
agents;2-4 and in the wake of recent atrocities there has been
renewed apprehension regarding the deployment of
chemical and biological weapons.5
Potential sources of exposure for civilian population
include acts of terrorism, inadvertent releases from
domestic chemical weapon stockpiles, direct military
attacks, and industrial accidents. The hostile use of CBW
agents would be likely to cause significant impact on health
care systems. Patient might present in unprecedented
numbers, and demands for intensive care might overwhelm
medical resources. Special medications or vaccines, not
generally available in standard pharmaceutical stocks,
might be required. Health care professionals and laboratory
personnel might need added physical protection. All these
problems can be overwhelming for the health care system,
but the efficacy of the medical response could be improved
if health care professionals were better aware of symptoms,
pathophysiology and treatment of agents likely to be used.5
There has been an increasing feeling amongst hospital
clinicians that there should be more awareness and
preparation about the management of casualties after a
terrorist attack using CBW agents.5-7
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We present an overview of the risk that chemical and
biological warfare agents presently pose to the civilian
population; and a discussion of the presentation and
principles of management of exposure to such agents.
Historical Background
The use of chemical and biological warfare agents as
weapons has been attempted throughout the history. Biological
warfare has evolved from the crude use of cadavers to
contaminate water supplies, to the development of specialized
munitions for battlefield and covert use. Recognition of the
potential impact of infectious disease on armies resulted in the
crude use of filth, cadavers, animal carcasses and contagion as
weapons. These have been used to contaminate water supplies
since antiquity, through the Napoleonic era, and into the 21st
century. Allegations have been made since World War I, but
these have not been confirmed because of the absence of
microbiological or epidemiological data.8 These incidents
underscore the difficulty in differentiating biological attacks
from naturally occurring epidemics and endemic diseases, and
emphasize the increased risk of epidemics during hostilities
because of deteriorating hygiene, sanitation and public health
infrastructure.9 The practice of ascribing naturally occurring
epidemic or endemic diseases to alleged biological attacks for
propaganda purposes, demonstrates the perception of
psychological vulnerability to the threat of biological warfare.
Despite all the limitations, concern continues to grow regarding
the possibility of proliferation or enhancement of state
sponsored offensive biological weapons programs and the
possible use of biological weapons by terrorist organizations.

206

